Jena University Hospital, Friedrich Schiller University, Institute of Human Genetics, Jena, Germany.
Division of Pediatric Neurology and Metabolic Medicine, Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Genet Med. 2019 Oct;21(10):2208-2215. doi: 10.1038/s41436-019-0480-7. Epub 2019 Mar 22.
Krabbe disease (OMIM 245200) is an orphan neurometabolic disorder caused by a deficiency of the lysosomal enzyme galactocerebrosidase (GALC). Hard clinical endpoints and biomarker-phenotype correlations are useful for future clinical trials.
We performed a quantitative analysis of published cases (N = 248) with Krabbe disease, stratified by age at disease onset: early infantile (age 0-6 months), late infantile (age 7-36 months), juvenile/adolescent (age 37-180 months), and adult onset (>180 months). Main outcome measures were age of disease onset and survival. Cerebrospinal fluid (CSF) protein concentrations were explored as a potential predictor of survival. STROBE criteria were respected.
Median age of onset was 4 months (early infantile), 14 months (late infantile), 48 months (juvenile), and 384 months (adult). Age of disease onset and therefore disease subtype determined survival rates. CSF protein concentrations predicted age at onset and survival rates in Krabbe disease. Patients with a CSF protein content ≤61.5 mg/dl survived significantly longer than patients with CSF protein values above this threshold.
We define the estimated survival in published Krabbe disease cases and demonstrate an association of CSF protein concentration with disease severity. These data inform patient care and clinical trials.
克拉伯病(OMIM 245200)是一种孤儿神经代谢疾病,由溶酶体酶半乳糖脑苷脂酶(GALC)缺乏引起。硬终点和生物标志物-表型相关性对于未来的临床试验很有用。
我们对已发表的克拉伯病病例(N=248)进行了定量分析,按发病年龄分层:早发性婴儿期(0-6 月龄)、晚发性婴儿期(7-36 月龄)、青少年/成年期(37-180 月龄)和成人发病(>180 月龄)。主要结局指标为发病年龄和生存率。探讨脑脊液(CSF)蛋白浓度作为生存的潜在预测指标。遵守 STROBE 标准。
发病年龄的中位数分别为 4 个月(早发性婴儿期)、14 个月(晚发性婴儿期)、48 个月(青少年期)和 384 个月(成年期)。发病年龄和因此发病类型决定了生存率。CSF 蛋白浓度可预测克拉伯病的发病年龄和生存率。CSF 蛋白含量≤61.5mg/dl 的患者的存活时间明显长于 CSF 蛋白值高于该阈值的患者。
我们定义了已发表的克拉伯病病例的估计生存率,并证明了 CSF 蛋白浓度与疾病严重程度相关。这些数据为患者护理和临床试验提供了信息。